P Camps

Summary

Affiliation: Universitat de Barcelona
Country: Spain

Publications

  1. ncbi request reprint Synthesis, in vitro pharmacology, and molecular modeling of syn-huprines as acetylcholinesterase inhibitors
    P Camps
    Laboratori de Química Farmacèutica, Facultat de Farmacia, Universitat de Barcelona, Av Diagonal 643, E 08028, Barcelona, Spain
    J Med Chem 44:4733-6. 2001
  2. ncbi request reprint New tacrine-huperzine A hybrids (huprines): highly potent tight-binding acetylcholinesterase inhibitors of interest for the treatment of Alzheimer's disease
    P Camps
    Laboratori de Quimica Farmaceutica and Departament de Fisico Quimica, Facultat de Farmacia, Universitat de Barcelona, Av Diagonal 643, E 08028 Barcelona, Spain
    J Med Chem 43:4657-66. 2000
  3. ncbi request reprint Cholinergic drugs in pharmacotherapy of Alzheimer's disease
    P Camps
    Laboratori de Química Farmacèutica, Facultat de Farmacia, Universitat de Barcelona, Spain
    Mini Rev Med Chem 2:11-25. 2002
  4. ncbi request reprint Tacrine-huperzine A hybrids (huprines): a new class of highly potent and selective acetylcholinesterase inhibitors of interest for the treatment of Alzheimer's disease
    P Camps
    Laboratori de Química Farmacèutica, Facultat de Farmacia, Universitat de Barcelona, Av Diagonal 643, E 08028, Barcelona, Spain
    Mini Rev Med Chem 1:163-74. 2001
  5. ncbi request reprint Nicotinic-receptor potentiator drugs, huprine X and galantamine, increase ACh release by blocking AChE activity but not acting on nicotinic receptors
    S Roman
    Departament de Farmacologia, de Terapeutica i de Toxicologia, Universitat Autonoma de Barcelona, Institut de Neurociències Universitat Autònoma de Barcelona, 08193 Bellaterra, Barcelona, Spain
    Brain Res 1061:73-9. 2005
  6. ncbi request reprint Effect of acetylcholinesterase inhibitors on AChE-induced PrP106-126 aggregation
    M V Clos
    Departamento de Farmacologia, de Terapèutica, i de Toxicologia, Instituto Neurociències, UAB, Barcelona, Spain
    J Mol Neurosci 30:89-90. 2006
  7. ncbi request reprint Acetylcholinesterase triggers the aggregation of PrP 106-126
    M Pera
    Departament de Farmacologia, de Terapeutica i de Toxicologia, Institut Neurociències, Universitat Autonoma de Barcelona, Barcelona, Spain
    Biochem Biophys Res Commun 346:89-94. 2006
  8. ncbi request reprint (+/-)-huprine Y, (-)-huperzine A and tacrine do not show neuroprotective properties in an apoptotic model of neuronal cytoskeletal alteration
    E G Jordà
    Unitat de Farmacologia i Farmacognosia, Barcelona, Spain
    J Alzheimers Dis 6:577-83; discussion 673-81. 2004
  9. ncbi request reprint Dimeric and hybrid anti-Alzheimer drug candidates
    D Muñoz-Torrero
    Laboratori de Química Farmacèutica, Unitat Associada al CSIC, Facultat de Farmacia, Universitat de Barcelona, Av Diagonal 643, E 08028 Barcelona, Spain
    Curr Med Chem 13:399-422. 2006
  10. ncbi request reprint The pharmacology of novel acetylcholinesterase inhibitors, (+/-)-huprines Y and X, on the Torpedo electric organ
    E Ros
    , Facultat de Medicina, Hospital de Bellvitge, Universitat de Barcelona, Campus de Bellvitge, , Feixa Llarga s/n, E-08907, L'Hospitalet de Llobregat, Spain
    Eur J Pharmacol 421:77-84. 2001

Collaborators

  • D Muñoz-Torrero
  • M Salmona
  • E Gomez
  • S Roman
  • M V Clos
  • A Badia
  • M Pera
  • M Ratia
  • L Colombo
  • E G Jordà
  • H Dvir
  • E Ros
  • C Manzoni
  • M Pallas
  • A M Canudas
  • E Verdaguer
  • A Camins
  • V Rimbau
  • A Jimenez
  • F J Luque
  • M Orozco
  • D M Wong
  • M Harel
  • T L Rosenberry
  • I Silman
  • X Barril
  • J L Sussman
  • C Solsona
  • J Aleu
  • J Marsal

Detail Information

Publications12

  1. ncbi request reprint Synthesis, in vitro pharmacology, and molecular modeling of syn-huprines as acetylcholinesterase inhibitors
    P Camps
    Laboratori de Química Farmacèutica, Facultat de Farmacia, Universitat de Barcelona, Av Diagonal 643, E 08028, Barcelona, Spain
    J Med Chem 44:4733-6. 2001
    ..Molecular modeling simulations allow us to explain the differences in inhibitory activity of these compounds on the basis of an inverse solvation effect...
  2. ncbi request reprint New tacrine-huperzine A hybrids (huprines): highly potent tight-binding acetylcholinesterase inhibitors of interest for the treatment of Alzheimer's disease
    P Camps
    Laboratori de Quimica Farmaceutica and Departament de Fisico Quimica, Facultat de Farmacia, Universitat de Barcelona, Av Diagonal 643, E 08028 Barcelona, Spain
    J Med Chem 43:4657-66. 2000
    ..Molecular modeling simulations of the AChE-inhibitor complex provided a basis to explain the differences in inhibitory activity of these compounds...
  3. ncbi request reprint Cholinergic drugs in pharmacotherapy of Alzheimer's disease
    P Camps
    Laboratori de Química Farmacèutica, Facultat de Farmacia, Universitat de Barcelona, Spain
    Mini Rev Med Chem 2:11-25. 2002
    ..Recent evidence of a potential disease modifying role of acetylcholinesterase inhibitors and M(1) muscarinic agonists have led to a revival of this approach, which might be considered as more than a symptomatic treatment...
  4. ncbi request reprint Tacrine-huperzine A hybrids (huprines): a new class of highly potent and selective acetylcholinesterase inhibitors of interest for the treatment of Alzheimer's disease
    P Camps
    Laboratori de Química Farmacèutica, Facultat de Farmacia, Universitat de Barcelona, Av Diagonal 643, E 08028, Barcelona, Spain
    Mini Rev Med Chem 1:163-74. 2001
    ....
  5. ncbi request reprint Nicotinic-receptor potentiator drugs, huprine X and galantamine, increase ACh release by blocking AChE activity but not acting on nicotinic receptors
    S Roman
    Departament de Farmacologia, de Terapeutica i de Toxicologia, Universitat Autonoma de Barcelona, Institut de Neurociències Universitat Autònoma de Barcelona, 08193 Bellaterra, Barcelona, Spain
    Brain Res 1061:73-9. 2005
    ....
  6. ncbi request reprint Effect of acetylcholinesterase inhibitors on AChE-induced PrP106-126 aggregation
    M V Clos
    Departamento de Farmacologia, de Terapèutica, i de Toxicologia, Instituto Neurociències, UAB, Barcelona, Spain
    J Mol Neurosci 30:89-90. 2006
    ....
  7. ncbi request reprint Acetylcholinesterase triggers the aggregation of PrP 106-126
    M Pera
    Departament de Farmacologia, de Terapeutica i de Toxicologia, Institut Neurociències, Universitat Autonoma de Barcelona, Barcelona, Spain
    Biochem Biophys Res Commun 346:89-94. 2006
    ..Huprines (AChE inhibitors) also significantly decreased MSA induced by AChE as well, unveiling the potential interest for some AChE inhibitors as a novel class of potential anti-prion drugs...
  8. ncbi request reprint (+/-)-huprine Y, (-)-huperzine A and tacrine do not show neuroprotective properties in an apoptotic model of neuronal cytoskeletal alteration
    E G Jordà
    Unitat de Farmacologia i Farmacognosia, Barcelona, Spain
    J Alzheimers Dis 6:577-83; discussion 673-81. 2004
    ..Although some of these drugs are of interest to treat Alzheimer's disease, their lack of efficacy in the prevention of colchicine-induced apoptosis in CGNs suggests that they cannot prevent neuronal loss due to cytoskeleton alteration...
  9. ncbi request reprint Dimeric and hybrid anti-Alzheimer drug candidates
    D Muñoz-Torrero
    Laboratori de Química Farmacèutica, Unitat Associada al CSIC, Facultat de Farmacia, Universitat de Barcelona, Av Diagonal 643, E 08028 Barcelona, Spain
    Curr Med Chem 13:399-422. 2006
    ..Herein, we review from a structural point of view the main classes of dimeric or hybrid compounds developed for the treatment of Alzheimer's disease, along with the pharmacological profile of the most active compounds...
  10. ncbi request reprint The pharmacology of novel acetylcholinesterase inhibitors, (+/-)-huprines Y and X, on the Torpedo electric organ
    E Ros
    , Facultat de Medicina, Hospital de Bellvitge, Universitat de Barcelona, Campus de Bellvitge, , Feixa Llarga s/n, E-08907, L'Hospitalet de Llobregat, Spain
    Eur J Pharmacol 421:77-84. 2001
    ..The interaction of (+/-)-huprine X with nicotinic receptors is weaker than that of (+/-)-huprine Y, suggesting that (+/-)-huprine X would be more specific to maintain the extracellular acetylcholine concentration...
  11. ncbi request reprint Potentiation effects of (+/-)huprine X, a new acetylcholinesterase inhibitor, on nicotinic receptors in rat cortical synaptosomes
    S Roman
    Departament de Farmacologia, de Terapeutica i de Toxicologia, Facultat de Medicina, Universitat Autonoma de Barcelona, 08193 Bellaterra, Barcelona, Spain
    Neuropharmacology 46:95-102. 2004
    ..05). While the results suggest that huprine may enhance the potency or effectiveness of ACh by an effect involving nicotinic receptors we cannot completely discard that the results could be explained by acetylcholine esterase inhibition...
  12. ncbi request reprint 3D structure of Torpedo californica acetylcholinesterase complexed with huprine X at 2.1 A resolution: kinetic and molecular dynamic correlates
    H Dvir
    Department of Structural Biology, Weizmann Institute of Science, Rehovot, Israel, 76100
    Biochemistry 41:2970-81. 2002
    ..Both (-)-huperzine A and huprine X display slow binding properties, but only binding of the former causes a peptide flip of Gly117...